Peptide News Digest

#Deloitte

1 story

Industry · View digest

Deloitte Will Stop Covering GLP-1 Drugs for Weight Loss in Its U.S. Medical Plans

Deloitte will no longer cover GLP-1 drugs prescribed for weight loss and will raise deductibles and out-of-pocket maximums in most health plans, according to an internal benefits guide seen by Business Insider, which reported the change on November 12. The drugs stay covered for diabetes and other covered conditions; for weight loss, the firm is offering eMed, a virtual lifestyle program with coaching and a $125-per-prescription employer contribution. The guide covers most of Deloitte's client-facing professionals (the firm employs about 181,000 people in the U.S.), and Business Insider noted that PwC and Starbucks also cut weight-loss coverage this year.